New research article in The Lancet HIV>

Efficacy, safety, and tolerability of switching to long-acting #cabotegravir plus #rilpivirine versus continuing fixed-dose #bictegravir, #emtricitabine, and #tenofovir alafenamide in virologically suppressed adults with #HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00136-4/fulltext

New research article in The Lancet HIV>

Pregnancy and neonatal safety outcomes of timing of initiation of daily oral #tenofovir disoproxil fumarate and #emtricitabine pre-exposure prophylaxis for #HIV prevention (CAP016): an open-label, randomised, non-inferiority trial

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00369-1/fulltext

#PrEP